De Novo device
EaseVRx
Appliedvr, Inc. · Virtual Reality Behavioral Therapy Device For Pain Relief (QRA, Class II) · First FDA decision Nov 16, 2021, newest Nov 16, 2021Chronic pain
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
9
Naming "EaseVRx"
MAUDE reports
0
Brand "EaseVRx", since 2015
PubMed studies
4
Mentioning "EaseVRx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EaseVRx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- EaseVRxNew device typeBreakthroughDe Novo
DEN210014 · Decided Nov 16, 2021 · 231 days after receipt
Device type: Virtual Reality Behavioral Therapy Device For Pain Relief (QRA) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Intensive Behavioral Therapy for ObesityNational analysisReview closedCAG-00423NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational analysisReview closedCAG-00424NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for ObesityNational determinationOn the books210.12Updated Dec 2, 2024
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational determinationOn the books210.11Updated Dec 2, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "EaseVRx", any status and sponsor, newest update first.
- Pragmatic Comparative Effectiveness Trial of Evidence-based, On-demand, Digital Behavioral Treatments for Chronic PainPivotal-lookingCompleted
Cedars-Sinai Medical CenterAcademic, hospital or other
NCT04933474 · 330 participants · Start Mar 23, 2022 · Primary completion May 12, 2024
Device: Skills-Based VR · For: Chronic Pain
Sites: Los Angeles, California
- Virtual Reality Therapy for Chronic Low Back PainPivotal-lookingCompleted
Cedars-Sinai Medical CenterAcademic, hospital or other
NCT04409353 · 413 participants · Start Sep 21, 2020 · Primary completion Oct 17, 2023
Device: Distraction-Based VR; Sham VR and 2 more · For: Chronic Low Back Pain
Sites: Los Angeles, California
Emory UniversityAcademic, hospital or other
NCT04906707 · 44 participants · Start Oct 27, 2021 · Primary completion Mar 5, 2024
Device: EaseVRx · For: Sickle Cell Disease
Sites: Atlanta, Georgia
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EaseVRx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QRA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EaseVRx"[tiab]. The summary above synthesizes these.
- An 8-Week Self-Administered At-Home Behavioral Skills-Based Virtual Reality Program for Chronic Low Back Pain: Double-Blind, Randomized, Placebo-Controlled Trial Conducted During COVID-19.
Garcia LM, Birckhead BJ, Krishnamurthy P, et al. · J Med Internet Res · 2021Randomized Controlled Trial
- Durability of the Treatment Effects of an 8-Week Self-administered Home-Based Virtual Reality Program for Chronic Low Back Pain: 6-Month Follow-up Study of a Randomized Clinical Trial.
Garcia L, Birckhead B, Krishnamurthy P, et al. · J Med Internet Res · 2022Randomized Controlled Trial
- Preliminary Benefits of In-Home Virtual Reality for Chronic Pain in Sickle Cell Disease: Pilot Randomized Trial.
Matthie N, Higgins M, Jenerette C · Biomedicines · 2026
- Self-Administered Behavioral Skills-Based At-Home Virtual Reality Therapy for Chronic Low Back Pain: Protocol for a Randomized Controlled Trial.
Garcia LM, Darnall BD, Krishnamurthy P, et al. · JMIR Res Protoc · 2021
Other devices of this type
Also filed under product code QRA.
- VrntCognifisense, Inc. · 510(k) 2026
- RelieVRx (Pico G3)Appliedvr · 510(k) 2025
- Smileyscope System (Therapy Mode)Smileyscope Holding, Inc. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.